High-Sensitivity C-Reactive Protein As a Biomarker in Detecting Subclinical Atherosclerosis in Psoriasis Publisher Pubmed



Niknezhad N¹ ; Haghighatkhah HR² ; Zargari O¹ ; Ghalamkarpour F¹ ; Younespour S³ ; Niknejad N⁴ ; Alikhan A⁵ ; Abdollahimajd F^{1, 6} Show Affiliations
Source: Dermatologic Therapy Published:2020

Abstract

Psoriasis is known to be associated with increased risk of cardiovascular diseases. High-sensitivity C-reactive protein (hs-CRP) is a marker of inflammation and an independent risk factor for atherosclerosis. We aimed to assess the correlation between hs-CRP and subclinical atherosclerosis in psoriatic patients. In 60 patients with moderate to severe psoriasis and 60 age- and gender matched healthy controls, we evaluated the serum hs-CRP level and mean intima-media thickness of the common carotid artery (MIMT-CCA). Psoriatic patients had higher levels of hs-CRP (median, 2.25 mg/L; IQR, 0.98-3.80; and range, 0.29-11.60) than did those in the control group (median, 1.03 mg/L; IQR, 0.36-2.15; and range, 0.10-3.35). Psoriatic patients also had higher mean MIMT (0.74 ± 0.19 and 0.54 ± 0.12, respectively, and P <.0001) compared with healthy subjects. The serum level of hs-CRP was significantly correlated with MIMT (P <.0001). Our results indicate that psoriatic patients have a higher risk of subclinical atherosclerosis and hs-CRP may be a useful marker for future risk of cardiovascular diseases in these patients. So, not only does anti-inflammatory drugs play a key role in the treatment of psoriasis, but also they may reduce the risk of cardiovascular diseases by decreasing level of inflammatory markers including hs-CRP. © 2020 Wiley Periodicals LLC.